DK3921030T3 - 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea-derivater som kcnq-potentiatorer - Google Patents
1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea-derivater som kcnq-potentiatorer Download PDFInfo
- Publication number
- DK3921030T3 DK3921030T3 DK20709409.5T DK20709409T DK3921030T3 DK 3921030 T3 DK3921030 T3 DK 3921030T3 DK 20709409 T DK20709409 T DK 20709409T DK 3921030 T3 DK3921030 T3 DK 3921030T3
- Authority
- DK
- Denmark
- Prior art keywords
- kcnq
- potentiators
- trifluoroethoxy
- pyridin
- methyl
- Prior art date
Links
- VDRSSRINXUQZRZ-UHFFFAOYSA-N [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methylurea Chemical class FC(COC1=NC=CC(=C1)CNC(=O)N)(F)F VDRSSRINXUQZRZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/016499 WO2020163268A1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3921030T3 true DK3921030T3 (da) | 2024-01-02 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20709409.5T DK3921030T3 (da) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea-derivater som kcnq-potentiatorer |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11208383B2 (da) |
| EP (1) | EP3921030B1 (da) |
| JP (2) | JP7451543B2 (da) |
| KR (1) | KR20210126040A (da) |
| CN (1) | CN113692304A (da) |
| AU (1) | AU2020218180A1 (da) |
| BR (1) | BR112021015544A2 (da) |
| CA (1) | CA3128975A1 (da) |
| DK (1) | DK3921030T3 (da) |
| ES (1) | ES2968807T3 (da) |
| FI (1) | FI3921030T3 (da) |
| HR (1) | HRP20240012T1 (da) |
| HU (1) | HUE064734T2 (da) |
| IL (1) | IL285113A (da) |
| LT (1) | LT3921030T (da) |
| MX (1) | MX2021009396A (da) |
| PL (1) | PL3921030T3 (da) |
| PT (1) | PT3921030T (da) |
| RS (1) | RS65040B1 (da) |
| SG (1) | SG11202108599SA (da) |
| SI (1) | SI3921030T1 (da) |
| WO (1) | WO2020163268A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3128975A1 (en) * | 2019-02-06 | 2020-08-13 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
| MX2022016263A (es) | 2020-06-25 | 2023-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de ciclobutil-urea. |
| WO2023054626A1 (ja) * | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | シクロプロパンアミド誘導体 |
| WO2023091461A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Pyridine compounds as kv7.2 enhancers |
| WO2023091554A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
| WO2023121992A1 (en) | 2021-12-22 | 2023-06-29 | Icagen, Llc | Cyclopropyl compounds |
| WO2023158584A1 (en) | 2022-02-15 | 2023-08-24 | Icagen, Llc | New bicyclopentane derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532676A (ja) | 2004-04-13 | 2007-11-15 | イカジェン インコーポレイテッド | カリウムイオンチャネル調節剤としての多環式ピリジン |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| ES2817902T3 (es) | 2013-03-15 | 2021-04-08 | Deciphera Pharmaceuticals Llc | N-acil-N'-(piridin-2-il) ureas y análogos que presentan actividades anticancerosas y antiproliferativas |
| WO2015130905A1 (en) * | 2014-02-27 | 2015-09-03 | Merck Patent Gmbh | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| CN107108485B (zh) | 2014-10-24 | 2020-06-12 | 小野药品工业株式会社 | Kcnq2～5通道活化剂 |
| EP3447045B9 (en) | 2016-04-22 | 2021-07-21 | ONO Pharmaceutical Co., Ltd. | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria |
| CA3128975A1 (en) * | 2019-02-06 | 2020-08-13 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
-
2020
- 2020-02-04 CA CA3128975A patent/CA3128975A1/en active Pending
- 2020-02-04 KR KR1020217028040A patent/KR20210126040A/ko unknown
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 AU AU2020218180A patent/AU2020218180A1/en active Pending
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 CN CN202080012797.0A patent/CN113692304A/zh active Pending
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en active Application Filing
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
-
2021
- 2021-07-25 IL IL285113A patent/IL285113A/en unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US20240076269A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022519744A (ja) | 2022-03-24 |
| US20220073464A1 (en) | 2022-03-10 |
| EP3921030A1 (en) | 2021-12-15 |
| CA3128975A1 (en) | 2020-08-13 |
| US11840516B2 (en) | 2023-12-12 |
| JP2024063191A (ja) | 2024-05-10 |
| ES2968807T3 (es) | 2024-05-14 |
| US11208383B2 (en) | 2021-12-28 |
| KR20210126040A (ko) | 2021-10-19 |
| JP7451543B2 (ja) | 2024-03-18 |
| BR112021015544A2 (pt) | 2021-10-26 |
| RS65040B1 (sr) | 2024-02-29 |
| MX2021009396A (es) | 2021-09-10 |
| PL3921030T3 (pl) | 2024-05-06 |
| HUE064734T2 (hu) | 2024-04-28 |
| US20240076269A1 (en) | 2024-03-07 |
| HRP20240012T1 (hr) | 2024-03-29 |
| EP3921030B1 (en) | 2023-10-11 |
| PT3921030T (pt) | 2024-01-12 |
| US20200247752A1 (en) | 2020-08-06 |
| SG11202108599SA (en) | 2021-09-29 |
| AU2020218180A1 (en) | 2021-08-19 |
| FI3921030T3 (fi) | 2024-01-08 |
| IL285113A (en) | 2021-09-30 |
| LT3921030T (lt) | 2024-01-25 |
| CN113692304A (zh) | 2021-11-23 |
| WO2020163268A1 (en) | 2020-08-13 |
| SI3921030T1 (sl) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3921030T3 (da) | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea-derivater som kcnq-potentiatorer | |
| DK3833670T3 (da) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorphenyl)-2-methylpyrimidin-4(3h)-on-derivater og lignende forbindelser som PTPN11- (SHP2) hæmmere til cancerbehandling | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| DK2272517T3 (da) | Orto-kondenserede pyridin- og pyrimidinderivater (f.eks. puriner) som proteinkinaseinhibitorer | |
| DK2445903T3 (da) | 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer | |
| DK1711177T3 (da) | 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer | |
| BR112017016458A2 (pt) | nó, controlador de rede, e métodos associados para rotear pacotes de dados em uma rede | |
| DK1954668T3 (da) | Homo- og heterocykliske forbindelser, der er egnede som CETP-inhibitorer | |
| DK1599450T3 (da) | Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister | |
| DK3418275T3 (da) | Hidtil ukendt 2,3,5-substitueret thiophenforbindelse som proteinkinasehæmmer | |
| IL252844B (en) | Process for preparing 4-(3-(-6-cyano-5-(trifluoromethyl)pyridin-3-yl)-4-oxo-2-thio-3,1-diazaspiro[5,4]-octan-1-yl) -2- fluoro-n-methylbenzamide | |
| DK3054927T3 (da) | Formuleringer af (s)-3-(4-((4-morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion | |
| DK1828166T3 (da) | Hydantoinderivater, der kan anvendes som metalloproteinase-inhibitorer | |
| EP3927696C0 (en) | CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOCINOLINE-5-YL)-5-(TRIFLUORMETHYL)-(2-(TRIFLUORMETHYL)PYRIDINE-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE MONOHYDRATE | |
| AR123656A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina | |
| DK3720438T3 (da) | Svampedræbende midler, der er afledt af heterocyklus-substitueret pyridin | |
| DK3861001T3 (da) | Bor, som indeholder PDE4-hæmmere | |
| MX2018006329A (es) | Agente terapeutico para cancer de mama. | |
| DK3559010T3 (da) | Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf | |
| DK1651640T3 (da) | Nicotinamid derivater, der er anvendelige som PDE4 inhibitorer | |
| DK3947711T3 (da) | Urinstofbiosensorer, der er stabiliseret ved rumtemperatur | |
| DK3827005T3 (da) | Pyridopyrimidiner som histamin H4-receptorhæmmere | |
| EP3733661A4 (en) | COMPOS &XC9; DE D &XC9; RIV &XC9; 2 - [5 -IMIDAZOLE - &XFF11; -YLM &XC9; THYL) PYRIDINE- &XFF13; -YL] BENZIMIDAZOLE, AND M &XC9; DICAMENT CONTAINING THIS ONE | |
| DK1390351T3 (da) | Pyrimidinderivater, der er nyttige som selektive COX-2-inhibitorer | |
| DK1900735T3 (da) | Pyridazinylamin-derivater, anvendelsen deraf til fremstilling af picornavirus-inhibitorer |